Accordingly, recently developed anti-IL-7R antibodies capable of binding both wild-type and mutant IL-7Rs have shown therapeutic efficacy in preclinical models, not only by delaying IL-7R+ T-ALL development and reducing tumor burden but also by exerting therapeutic action against chemotherapy-resistant relapsing disease [144,145]. This evidence concerns the gene IL7R and neoplasm.